SBIO

ALPS Medical Breakthroughs ETF

Up$33.92
+$0.67
(+2.02%)
As of 1:00:00 AM EDT | 2/15/19  |  Market Closed

SBIO Trading Data

Open

$33.45

Low Price

$33.31

High Price

$33.94

Previous Last Price

$33.25

Bid Size

$0 X 0

Ask Size

$0 X 0

SBIO Portfolio Data

AUM

$181,665,000

Shares

5,500

PE Ratio

12.55

Price / Book Ratio

3.39

Expense Ratio

0.5

Net Asset Value

$33.03

Volume

Volume

37,300

Avg. Volume (YDT)

46,434

Dollar Volume

$1,125,662

Weekly Avg. Volume

31,160

Monthly Avg. Volume

50,055

Quarterly Avg. Volume

75,893

SBIO Fund Description

The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States. It invests in the stocks of companies operating in the biotechnology and pharmaceutical sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the Poliwogg Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.

SBIO Chart

SBIO Summary

Fund Family

ALPS Holdings

Tracks This Index

ALPS Medical Breakthroughs ETF

Inception Date

2015-01-05

Asset Class

Portfolio-Multi Asset

Asset Class Size

Healthcare

SBIO Classification

Region (General)

Global

Region (Specific)

Sector

Health Care

Equity Index

Leveraged Family

SBIO Holdings

Top 10 Holdings

Cash and Equivalents
674%
FibroGen Inc. (FGEN)
581%
Array BioPharma Inc. (ARRY)
576%
United Therapeutics Corp. (UTHR)
444%
Agios Pharmaceuticals Inc. (AGIO)
403%
Galapagos NV (GLPG)
397%
Emergent BioSolutions Inc. (EBS)
394%
Ascendis Pharma AS (ASND)
361%
Global Blood Therapeutics Inc. (GBT)
338%
Immunomedics Inc. (IMMU)
305%

Total SBIO Holdings

Total Holdings: 72

Cash and Equivalents
674%
FibroGen Inc. (FGEN)
581%
Array BioPharma Inc. (ARRY)
576%
United Therapeutics Corp. (UTHR)
444%
Agios Pharmaceuticals Inc. (AGIO)
403%
Galapagos NV (GLPG)
397%
Emergent BioSolutions Inc. (EBS)
394%
Ascendis Pharma AS (ASND)
361%
Global Blood Therapeutics Inc. (GBT)
338%
Immunomedics Inc. (IMMU)
305%
Ligand Pharmaceuticals Inc. (LGND)
301%
Arena Pharmaceuticals Inc. (ARNA)
288%
Halozyme Therapeutics Inc. (HALO)
288%
Mirati Therapeutics Inc. (MRTX)
276%
Insmed Inc. (INSM)
244%
Madrigal Pharmaceuticals Inc. (MDGL)
243%
Enanta Pharmaceuticals Inc. (ENTA)
234%
Acceleron Pharma Inc. (XLRN)
230%
Atara Biotherapeutics Inc. (ATRA)
216%
AnaptysBio Inc. (ANAB)
214%
CRISPR Therapeutics AG (CRSP)
189%
PTC Therapeutics Inc. (PTCT)
175%
uniQure NV (QURE)
162%
Rhythm Pharmaceuticals Inc. (RYTM)
121%
Fate Therapeutics Inc. (FATE)
112%
MacroGenics Inc. (MGNX)
107%
Vericel Corp. (VCEL)
98%
ImmunoGen Inc. (IMGN)
98%
G1 Therapeutics Inc. (GTHX)
91%
Apellis Pharmaceuticals Inc. (APLS)
91%
Acorda Therapeutics Inc. (ACOR)
79%
Cara Therapeutics Inc. (CARA)
78%
UroGen Pharma Ltd. (URGN)
77%
Viking Therapeutics Inc. (VKTX)
75%
Akebia Therapeutics Inc. (AKBA)
74%
AMAG Pharmaceuticals Inc. (AMAG)
67%
Kura Oncology Inc. (KURA)
66%
Flexion Therapeutics Inc. (FLXN)
65%
ChemoCentryx Inc. (CCXI)
64%
GlycoMimetics Inc. (GLYC)
60%
Corbus Pharmaceuticals Holdings Inc. (CRBP)
60%
PDL BioPharma Inc. (PDLI)
57%
Progenics Pharmaceuticals Inc. (PGNX)
48%
Five Prime Therapeutics Inc. (FPRX)
48%
NuCana PLC (NCNA)
43%
ArQule Inc. (ARQL)
43%
Concert Pharmaceuticals Inc. (CNCE)
41%
Voyager Therapeutics Inc. (VYGR)
41%
CASI Pharmaceuticals Inc. (CASI)
40%
Krystal Biotech Inc. (KRYS)
39%
Achillion Pharmaceuticals Inc. (ACHN)
38%
Aduro Biotech Inc. (ADRO)
37%
MediciNova Inc. (MNOV)
37%
Abeona Therapeutics Inc. (ABEO)
37%
Albireo Pharma Inc. (ALBO)
37%
Minerva Neurosciences Inc. (NERV)
35%
Adamas Pharmaceuticals Inc. (ADMS)
33%
Catalyst Pharmaceuticals Inc. (CPRX)
33%
Kiniksa Pharmaceuticals Ltd. (KNSA)
32%
AC Immune SA (ACIU)
31%
Savara Inc. (SVRA)
28%
Synlogic Inc. (SYBX)
28%
Syros Pharmaceuticals Inc. (SYRS)
27%
Tocagen Inc. (TOCA)
25%
Athersys Inc. (ATHX)
25%
MEI Pharma Inc. (MEIP)
25%
Arbutus Biopharma Corp. (ABUS)
25%
Calithera Biosciences Inc. (CALA)
24%
Xenon Pharmaceuticals Inc. (XENE)
24%
State Street Institutional Treasury Plus Money Market Fund (TPIXX)
3%
ALPS Medical Breakthroughs ETF (SBIO)
0%
Corium International Inc (CORI-CVR)
0%

SBIO Technicals

Alpha

-8.64

Beta

1.69

Leverage

Long

Standard Deviation

3.01

SBIO Dividends

Dividend Date

2018-12-20

Latest Dividend

0.784

Annual Dividend

0.78

Annual Dividend Rate

0.78

Annual Dividend Yield

2.37

SBIO Performance

YTD Return

20.54%

1 Year Return

-5.17%

3 Year Return

51.7%

5 Year Return

0%

10 Year Return

36.55%

SBIO Related Articles

A Nifty Biotech ETF Idea for 2018

A Nifty Biotech ETF Idea for 2018

Biotechnology stocks bolstered the broader healthcare sector last year, a theme that is expected to continue in 2018. Investors looking…